Key facts
- Notable investors include Mission BioCapital, MassBio.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Laurel Biotherapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Laurel Biotherapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Laurel Biotherapeutics
Developer of antibody-based therapeutics designed to treat cardiovascular and related metabolic and inflammatory diseases. The company's platform integrates artificial intelligence-driven design with immune-derived discovery to produce modular, single-domain, and monoclonal antibody formats that target the interconnected pathways between the heart, kidneys, and metabolic systems, enabling patients with chronic cardiovascular conditions to reduce their dependence on multiple daily medications.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2024
- Employees
- 3
- Website
- laurelbio.com/
- Ownership
- Privately Held (backing)
Laurel Biotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Laurel Biotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Laurel Biotherapeutics in its N-PORT filings yet. We sweep new filings monthly.